FDA Updates Prescribing Information for PAH Treatment Winrevair
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Merck's PAH treatment Winrevair (sotatercept-csrk).
The update specifies that Winrevair reduces the risk of serious complications, including hospitalization for PAH, lung transplant, and death, in adults with pulmonary arterial hypertension (PAH).
Winrevair was approved by the FDA last year to improve exercise capacity, improve World Health Organization (WHO) functional class, and reduce the risk of clinical worsening events in adults with PAH.
- Improves exercise capacity
- Improves World Health Organization (WHO) functional class
- Reduces the risk of clinical worsening events, including:
- Hospitalization for PAH
- Lung transplant
- Death
Author's summary: FDA updates Winrevair's prescribing information to reflect reduced risk of lung transplant and death.
More News
- 'Secretly they continue to live within us and through us' – Baptist News Global
- Will ARC Raiders Survive? A Deep Dive Into Its Future | Invision Game Community
- Austin Reaves cracks viral joke after buzzer-beater lifts Lakers to win
- Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times - Clinical Insights for Eye Specialists
- Dutch election: D66 and PVV neck and neck with smallest difference ever
- Intuition and AI - Vital Role - I by IMD
- CXMT begins producing advanced LPDDR5X memory chips as China narrows tech gap
- Coats Group completes acquisition of OrthoLite, restructures divisions